INTEGRITI-TIMI 20

INTEGRITI-(TIMI 20) evaluated the safety and efficacy of the combination of eptifibatide and TNK among patients presenting with ST elevation myocardial infarction.

PRESENTATIONS

TIMI 20 Slides

PUBLICATIONS

Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction

Association of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction

Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction

Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction

Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy

Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction

Effect of rescue or adjunctive percutaneous coronary intervention of the culprit artery after fibrinolytic administration on epicardial flow in nonculprit arteries

Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial

 

 

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close